Athena Athena

X
[{"orgOrder":0,"company":"VIVEbiotech","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VIVEbiotech Collaborates with Xyphos Biosciences for Clinical Development Support Of Convertible CAR-T\u2122 Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SPAIN","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by VIVEbiotech

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The agreement covers VIVEbiotech long-term supplying lentiviral vectors for Xyphos’ upcoming clinical trial of its lead convertibleCAR-T™ program. This involves VIVEbiotech manufacturing lentiviral vectors for both preclinical and clinical phases.

            Lead Product(s): Lentiviral vectors,convertible CAR-T cells

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Xyphos Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 04, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY